Brand Name : Sprycel
Composition : Dasatinib
Strength availability : 70mg
Manufactured by : BMS India Pvt ltd
Form : Tablets
Pack : 60 tablets
for MORE INFORMATION !!!
Sprycel 70mg belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel, are BCRABL, SRC, Ephrin’s and GFR.
Sprycel 70mg is a prescription drug which used under the supervision of doctor.
Sprycel 70mg is indicated for the treatment of adult patients having chronic myeloid leukaemia.
Sprycel 70mg is indicated for the treatment of adult patients having acute lymphoblastic leukaemia.
Chronic Myeloid Leukaemia :
Sprycel indicated for adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase and Used for treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with support or intolerance to before therapy contains imatinib
Starting dose with 100 mg PO qDay (morning or evening).
May raised to 140 mg qDay if insufficient response.
Starting dose with 140 mg PO qDay
May increase to 180 mg qDay if insufficient reactions
Acute Lymphoblastic Leukaemia :
Sprycel indicated for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy
Initiate 140 mg PO qDay
May increase to 180 mg PO qDay if insufficient reactions.
Dasatinib is a group of drug which belongs to protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins which work as chemical messengers to stimulate cancer cells to develop. Dasatinib inhibits the tyrosine kinases from passing chemical signals which tell the cells to develop.
Distribution: volume of distribution 2505 L and plasma protein binding is 96%
Metabolism: Extensively metabolized in humans, mainly by the cytochrome P450 enzyme 3A4.
Elimination: Dasatinib excreted through the feces.
Half-life is 3-5 hours
Sprycel 70mg concomitant use with CYP3A4 inhibitors will increase Dasatinib plasma concentration.
Sprycel 70mg combination with CYP3A4 inducers will reduces Dasatinib plasma concentration.
Sprycel 70mg combination with antacids will decrease Dasatinib plasma concentration.
Sprycel 70mg combination with H2 antagonists/proton pump inhibitors will decrease Dasatinib plasma concentration.
Sprycel 70mg Interaction with CYP3A4 substrates will have their plasma concentration altered by Dasatinib.
Using of Sprycel will results in Tumor lysis syndrome; maintain sufficient hydration and correct uric acid levels before to starting treatment
Sprycel will causes Risk of fluid retention and pleural/pericardial effusion; manage with supportive care measures and/or dose modification
Myelosuppression which involves severe thrombocytopenia, neutropenia and Anemia may occurs; may manage by dose interference, dose reduction, or blocking of treatment; hematopoietic growth factor has been used with resistant myelosuppression
Advise females of reproductive possible to do not become pregnancy, which may contains the use of effective contraceptive methods, during treatment with Sprycel and for 30 days after the final dose.
Certain patients with chronic phase CML and paediatric Ph+ ALL, reveals complete blood cell counts (CBCs) q2Weeks for 12 weeks, then q3Months thereafter, or as clinically indicated; show CBCs for the first 2 months weekly after that monthly,
Store at 20℃ to 25℃.
In case of missed dose, patients must consult with medical oncologist and follow the regular dosing schedule.
• Skin rash
• Musculoskeletal pain
• Febrile neutropenia
• Mucosal inflammation